Katherine E Cain1, Maria D Iniesta2, Bryan M Fellman3, Tina S Suki2, Ashley Siverand2, Camila Corzo2, Javier D Lasala4, Juan P Cata4, Gabriel E Mena5, Larissa A Meyer2, Pedro T Ramirez2. 1. Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: kecain@mdanderson.org. 2. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Anesthesiology and Surgical Oncology Research Group, Houston, TX, USA. 5. Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
OBJECTIVE: Both intravenous (IV) and oral acetaminophen provide effective opioid-sparing analgesia after surgery when used as part of a multimodal preemptive pain management strategy. The purpose of this study was to compare postoperative opioid consumption in patients undergoing open gynecologic oncology surgery who received preoperative IV vs oral acetaminophen within an enhanced recovery after surgery (ERAS) program. METHODS: Retrospective data were collected on consecutive patients undergoing open gynecologic oncology surgery from May 1, 2016 to February 28, 2018 in patients receiving either 1 g IV or oral acetaminophen preoperatively. Patients were given a preoperative multimodal analgesia regimen including acetaminophen, celecoxib, pregabalin and tramadol. The primary outcomes were morphine equivalent daily doses (MEDD) on postoperative days (POD) 0 and 1. Secondary outcomes included highest patient-reported pain score in the post-anesthesia care unit (PACU) and intraoperative MEDD. Regression models adjusted by matched pairs were fit to estimate the average treatment effect of IV vs oral acetaminophen on MEDD. RESULTS: Of 353 patients, 178 (50.4%) received IV acetaminophen and 175 (49.6%) received oral acetaminophen. When balancing across the matched samples, there was no difference in postoperative MEDD for POD 0 between the IV and oral acetaminophen groups (Beta = -1.11; 95% CI: -4.83 to 2.60; p = 0.56). On POD 1, there was no difference between the IV and oral groups (Beta = 2.24; 95% CI: -2.76 to 7.25; p = 0.38). CONCLUSIONS: There was no difference in postoperative opioid consumption between patients receiving preoperative IV or oral acetaminophen within an ERAS program for patients undergoing open gynecologic oncology surgery.
OBJECTIVE: Both intravenous (IV) and oral acetaminophen provide effective opioid-sparing analgesia after surgery when used as part of a multimodal preemptive pain management strategy. The purpose of this study was to compare postoperative opioid consumption in patients undergoing open gynecologic oncology surgery who received preoperative IV vs oral acetaminophen within an enhanced recovery after surgery (ERAS) program. METHODS: Retrospective data were collected on consecutive patients undergoing open gynecologic oncology surgery from May 1, 2016 to February 28, 2018 in patients receiving either 1 g IV or oral acetaminophen preoperatively. Patients were given a preoperative multimodal analgesia regimen including acetaminophen, celecoxib, pregabalin and tramadol. The primary outcomes were morphine equivalent daily doses (MEDD) on postoperative days (POD) 0 and 1. Secondary outcomes included highest patient-reported pain score in the post-anesthesia care unit (PACU) and intraoperative MEDD. Regression models adjusted by matched pairs were fit to estimate the average treatment effect of IV vs oral acetaminophen on MEDD. RESULTS: Of 353 patients, 178 (50.4%) received IV acetaminophen and 175 (49.6%) received oral acetaminophen. When balancing across the matched samples, there was no difference in postoperative MEDD for POD 0 between the IV and oral acetaminophen groups (Beta = -1.11; 95% CI: -4.83 to 2.60; p = 0.56). On POD 1, there was no difference between the IV and oral groups (Beta = 2.24; 95% CI: -2.76 to 7.25; p = 0.38). CONCLUSIONS: There was no difference in postoperative opioid consumption between patients receiving preoperative IV or oral acetaminophen within an ERAS program for patients undergoing open gynecologic oncology surgery.
Authors: Gregg Nelson; Jamie Bakkum-Gamez; Eleftheria Kalogera; Gretchen Glaser; Alon Altman; Larissa A Meyer; Jolyn S Taylor; Maria Iniesta; Javier Lasala; Gabriel Mena; Michael Scott; Chelsia Gillis; Kevin Elias; Lena Wijk; Jeffrey Huang; Jonas Nygren; Olle Ljungqvist; Pedro T Ramirez; Sean C Dowdy Journal: Int J Gynecol Cancer Date: 2019-03-15 Impact factor: 3.437
Authors: Skip R Hickman; Kathleen M Mathieson; Lynne M Bradford; Casey D Garman; Richard W Gregg; Douglas W Lukens Journal: Am J Health Syst Pharm Date: 2018-03-15 Impact factor: 2.637
Authors: Neil K Singla; Cherri Parulan; Roselle Samson; Joel Hutchinson; Rick Bushnell; Evelyn G Beja; Robert Ang; Mike A Royal Journal: Pain Pract Date: 2012-04-24 Impact factor: 3.183
Authors: R Tyler Hillman; Amalia Sanchez-Migallon; Larissa A Meyer; Maria D Iniesta; Katherine E Cain; Ashley M Siverand; Simone P L Veum; Tina S Suki; Javier D Lasala; Pedro T Ramirez Journal: Gynecol Oncol Date: 2019-03-20 Impact factor: 5.482
Authors: Larissa A Meyer; Javier Lasala; Maria D Iniesta; Alpa M Nick; Mark F Munsell; Qiuling Shi; Xin Shelley Wang; Katherine E Cain; Karen H Lu; Pedro T Ramirez Journal: Obstet Gynecol Date: 2018-08 Impact factor: 7.661
Authors: Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary Journal: Healthcare (Basel) Date: 2021-03-16
Authors: Richard H Parrish; Heather Monk Bodenstab; Dustin Carneal; Ryan M Cassity; William E Dager; Sara J Hyland; Jenna K Lovely; Alyssa Pollock; Tracy M Sparkes; Siu-Fun Wong Journal: J Clin Med Date: 2022-09-24 Impact factor: 4.964